Elkeles will serve through the 2027 annual Shareholder meeting and receive compensation under the company’s non-employee director programme.

PETMED EXPRESS expanded its board to 5 directors by appointing Tamar Elkeles as an independent director effective September 17, 2026. Investors gain a board member assigned to compensation, human capital, governance and nominating committees, with the company citing her executive, advisory and board experience in strategic oversight.

Key Highlights

  • Tamar Elkeles joined PETMED EXPRESS as an independent director effective September 17, 2026.
  • Her appointment increased the board’s size to 5 directors.
  • Elkeles received 49,923 shares at $0 in connection with her insider position.

Tamar Elkeles became a director effective September 17, 2026, lifting the board to 5 members and adding an independent director with experience across technology, enterprise software and Human Capital industries.

Elkeles will remain on the board until the 2027 annual shareholder meeting, unless she resigns or is removed earlier, or a successor is elected and qualified. Nasdaq listing standards and the company’s Corporate Governance Guidelines classify her as independent. She will immediately serve on the Compensation and Human Capital Committee and the Corporate Governance and Nominating Committee. A separate insider transaction record shows an award of 49,923 PETMED EXPRESS (NASDAQ: PETS) shares at $0. The appointment carries compensation under PETMED EXPRESS’s Non-Employee Director Compensation Program. The company also intends to enter an indemnification agreement with Elkeles using the same form as its standard agreement with other directors. Her current board roles include Brightline Interactive (NASDAQ: BTLN) and OpenSesame.